Boston Scientific invests $1.5bn for equity stake in MiRus

Boston Scientific has announced a $1.5bn investment to acquire a 34% equity stake in implants and procedural solutions developer MiRus. Boston Scientific may acquire full ownership of MiRus’ TAVR business for an additional $3bn after achieving certain milestones. The valve utilises dry porcine tissue leaflets and a nitric oxide-coated rhenium frame exceeding cobalt or titanium. Credit: MAD.vertise / Shutterstock.com. Boston Scientific has announced a $1.5bn investment to acquire approximately a 34% equity stake in MiRus, a company developing the SIEGEL Balloon Expandable transcatheter aortic valve replacement (TAVR) system. According to the agreement, Boston Scientific also secured an exclusive option to…

Source: Medical Device Network